Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 1995;76:110-119

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salata, J. J.
Right arrow Articles by Lynch, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salata, J. J.
Right arrow Articles by Lynch, J. J., Jr
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ASTEMIZOLE
*CHLORPHENIRAMINE
*PYRILAMINE
*TERFENADINE
(Circulation Research. 1995;76:110-119.)
© 1995 American Heart Association, Inc.


Articles

Cardiac Electrophysiological Actions of the Histamine H1-Receptor Antagonists Astemizole and Terfenadine Compared With Chlorpheniramine and Pyrilamine

Joseph J. Salata, Nancy K. Jurkiewicz, Audrey A. Wallace, Raymond F. Stupienski, III, Peter J. Guinosso, Jr, Joseph J. Lynch, Jr

From the Department of Pharmacology, Merck Research Laboratories, West Point, Pa.

Correspondence to Joseph J. Salata, Department of Pharmacology, Merck Research Laboratories, Sumneytown Pike, PO Box 4, WP26-265, West Point, PA 19486.

Abstract We compared the cardiac electrophysiological actions of two types of H1-receptor antagonists—the piperidines, astemizole and terfenadine, and the nonpiperidines, chlorpheniramine and pyrilamine—in vitro in guinea pig ventricular myocytes and in vivo in chloralose-anesthetized dogs. Astemizole and terfenadine significantly increased action potential duration of guinea pig myocytes. This concentration-dependent prolongation of action potential duration was reverse frequency dependent and led to development of early afterdepolarizations, which occurred more frequently at higher concentrations and slower pacing frequencies. Astemizole and terfenadine potently blocked the rapidly activating component of the delayed rectifier, IKr, with IC50 values of 1.5 and 50 nmol/L, respectively. At 10 µmol/L, terfenadine but not astemizole blocked the slowly activating component of the delayed rectifier, IKs (58.4±3.1%), and the inward rectifier, IK1 (20.5±3.4%). Chlorpheniramine and pyrilamine blocked IKr relatively weakly (IC50=1.6 and 1.1 µmol/L, respectively) and IKs and IK1 less than 20% at 10 µmol/L. Astemizole and terfenadine (1.0 to 3.0 mg/kg IV) significantly prolonged the QTc interval and ventricular effective refractory period in vivo. Chlorpheniramine and pyrilamine (<=3.0 mg/kg) did not significantly affect these parameters. Block of repolarizing K+ currents, particularly IKr, by astemizole and terfenadine produces reverse rate–dependent prolongation of action potential duration and development of early afterdepolarizations, delays ventricular repolarization, and may underlie the development of torsade de pointes ventricular arrhythmias observed with the use and abuse of these agents.


Key Words: early afterdepolarization • delayed rectifier potassium current • torsade de pointes




This article has been cited by other articles:


Home page
Toxicol SciHome page
B. D. Guth
Preclinical Cardiovascular Risk Assessment in Modern Drug Development
Toxicol. Sci., May 1, 2007; 97(1): 4 - 20.
[Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Kang, X.-L. Chen, H. Wang, J. Ji, H. Cheng, J. Incardona, W. Reynolds, F. Viviani, M. Tabart, and D. Rampe
Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel
Mol. Pharmacol., March 1, 2005; 67(3): 827 - 836.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
P. Zimetbaum and M. E. Josephson
Is There a Role for Maintaining Sinus Rhythm in Patients with Atrial Fibrillation?
Ann Intern Med, November 2, 2004; 141(9): 720 - 726.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Kang, X.-L. Chen, H. Wang, J. Ji, W. Reynolds, S. Lim, J. Hendrix, and D. Rampe
Cardiac Ion Channel Effects of Tolterodine
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 935 - 940.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
C. Antzelevitch, L. Belardinelli, L. Wu, H. Fraser, A. C. Zygmunt, A. Burashnikov, J. M. Di Diego, J. M. Fish, J. M. Cordeiro, R. J. Goodrow Jr, et al.
Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2004; 9(1_suppl): S65 - S83.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. Wang, K. Della Penna, H. Wang, J. Karczewski, T. M. Connolly, K. S. Koblan, P. B. Bennett, and J. J. Salata
Functional and pharmacological properties of canine ERG potassium channels
Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H256 - H267.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. A. Fossa, M. J. DePasquale, D. L. Raunig, M. J. Avery, and D. J. Leishman
The Relationship of Clinical QT Prolongation to Outcome in the Conscious Dog Using a Beat-to-Beat QT-RR Interval Assessment
J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 828 - 833.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
D. Escande
Inhibition of repolarizing ionic currents by drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K17 - K22.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
A.E. Lacerda, J. Kramer, K.-Z. Shen, D. Thomas, and A.M. Brown
Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K23 - K30.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
L. Carlsson
Drug-induced torsade de pointes: the perspectives of industry
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K114 - K120.
[Abstract] [PDF]


Home page
Toxicol SciHome page
K. Yamamoto, T. Tamura, R. Imai, and M. Yamamoto
Acute Canine Model for Drug-Induced Torsades de Pointes in Drug Safety Evaluation--Influences of Anesthesia and Validation with Quinidine and Astemizole
Toxicol. Sci., March 1, 2001; 60(1): 165 - 176.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Geelen, B. Drolet, J. Rail, J. Berube, P. Daleau, G. Rousseau, R. Cardinal, G. E. O'Hara, and J. Turgeon
Sildenafil (Viagra) Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current
Circulation, July 18, 2000; 102(3): 275 - 277.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. J. Crumb Jr.
Loratadine Blockade of K+ Channels in Human Heart: Comparison with Terfenadine under Physiological Conditions
J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 261 - 264.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
L. M. Shuba, Y. Kasamaki, S. E. Jones, T. Ogura, J. R. McCullough, and T. F. McDonald
Action Potentials, Contraction, and Membrane Currents in Guinea Pig Ventricular Preparations Treated with the Antispasmodic Agent Terodiline
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1417 - 1426.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Khalifa, B. Drolet, P. Daleau, C. Lefez, M. Gilbert, S. Plante, G. E. O'Hara, O. Gleeton, B. A. Hamelin, and J. Turgeon
Block of Potassium Currents in Guinea Pig Ventricular Myocytes and Lengthening of Cardiac Repolarization in Man by the Histamine H1 Receptor Antagonist Diphenhydramine
J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 858 - 865.
[Abstract] [Full Text]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. Geelen, B. Drolet, E. Lessard, P. Gilbert, G. E. O'Hara, and J. Turgeon
Concomitant Block of the Rapid (IKr) and Slow (IKs) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(3): 143 - 150.
[Abstract] [PDF]


Home page
Hum Exp ToxicolHome page
A S. Davis
The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods
Human and Experimental Toxicology, December 1, 1998; 17(12): 677 - 680.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Nishio, Y. Habuchi, H. Tanaka, J. Morikawa, T. Yamamoto, and K. Kashima
Blockage by Terfenadine of the Adenosine Triphosphate (ATP)-Sensitive K+ Current in Rabbit Ventricular Myocytes
J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 293 - 300.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
M. Taglialatela, A. Pannaccione, P. Castaldo, G. Giorgio, Z. Zhou, C. T. January, A. Genovese, G. Marone, and L. Annunziato
Molecular Basis for the Lack of HERG K+ Channel Block-Related Cardiotoxicity by the H1 Receptor Blocker Cetirizine Compared with Other Second-Generation Antihistamines
Mol. Pharmacol., July 1, 1998; 54(1): 113 - 121.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
J. J. Salata, N. K. Jurkiewicz, J. Wang, B. E. Evans, H. T. Orme, and M. C. Sanguinetti
A Novel Benzodiazepine that Activates Cardiac Slow Delayed Rectifier K+ Currents
Mol. Pharmacol., July 1, 1998; 54(1): 220 - 230.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
X.-K. Liu, A. Katchman, M.-D. Drici, S. N. Ebert, I. Ducic, M. Morad, and R. L. Woosley
Gender Difference in the Cycle Length-Dependent QT and Potassium Currents in Rabbits
J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 672 - 679.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
M. Nabauer and S. Kaab
Potassium channel down-regulation in heart failure
Cardiovasc Res, February 1, 1998; 37(2): 324 - 334.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Drolet, M. Khalifa, P. Daleau, B. A. Hamelin, and J. Turgeon
Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval
Circulation, January 20, 1998; 97(2): 204 - 210.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
P. D. West, D. K. Martin, J. A. Bursill, K. R. Wyse, and T. J. Campbell
Comparative Study of the Effects of Erythromycin and Roxithromycin on Action Potential Duration and Potassium Currents in Canine Purkinje Fibers and Rabbit Myocardium
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(1): 29 - 36.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Fiset, B. Drolet, B. A. Hamelin, and J. Turgeon
Block of IKs by the Diuretic Agent Indapamide Modulates Cardiac Electrophysiological Effects of the Class III Antiarrhythmic Drug dl-Sotalol
J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 148 - 156.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
A. E. Lacerda, M.-L. Roy, E. W. Lewis, and D. Rampe
Interactions of the Nonsedating Antihistamine Loratadine with a Kv1.5-Type Potassium Channel Cloned from Human Heart
Mol. Pharmacol., August 1, 1997; 52(2): 314 - 322.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
E. Delpon, C. Valenzuela, P. Gay, L. Franqueza, D. J Snyders, and J. Tamargo
Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels
Cardiovasc Res, August 1, 1997; 35(2): 341 - 350.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. M. Ko, I. Ducic, J. Fan, Y. M. Shuba, and M. Morad
Suppression of Mammalian K+ Channel Family by Ebastine
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 233 - 244.
[Abstract] [Full Text]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Sicouri, S. Moro, and M. V. Elizari
d-Sotalol Induces Marked Action Potential Prolongation and Early Afterdepolarizations in M but Not Epicardial or Endocardial Cells of the Canine Ventricle
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 27 - 37.
[Abstract] [PDF]